By webmin on
Email
AbbviePAA@abbvie.com
ClinicalTrials.gov URL
https://clinicaltrials.gov
NCT Name
NCT04830202; NCT05982873; NCT07310277; NCT07158827; NCT04159597; NCT03123029
Acknowledgement
1 business day
EA Page
https://www.abbvie.com/who-we-are/access-to-investigational-drugs-policy.html
Sponsor
AbbVie
EA Therapies for Single Patient

ABBV-399 (Telisotuzumab Vedotin) 

Indications:

  • Non-Small Cell Lung Cancer 

ClinicalTrials.gov URL: https://clinicaltrials.gov/study/NCT04830202

 

ABBV-400 (Telisotuzumab Adizutecan)

Indications:

  • Solid Tumors

ClinicalTrials.gov URL: https://clinicaltrials.gov/study/NCT05982873

 

ABBV-706 

Indications:

  • Small Cell Lung Cancer
  • Treatment-Induced Small Cell Lung Cancer

ClinicalTrials.gov URL: https://clinicaltrials.gov/study/NCT07310277

 

Tavapadon 

Indication:

  • Parkinson’s Disease

ClinicalTrials.gov URL: https://clinicaltrials.gov/study/NCT07158827

 

Upadacitinib oral solution

Indications:

  • Ulcerative colitis (UC) 
  • Crohn's disease (CD) 
  • Juvenile idiopathic arthritis (including sJIA, pJlA or JPsA)
  • Rheumatoid Arthritis (RA)   
  • Psoriatic Arthritis (PsA)  
  • Axial Spondyloarthritis (axSpA) 
  • Non-radiographic Axial Spondyloarthritis (nr-axSpA) 
  • Giant Cell Arteritis (GCA)  
  • Systemic Lupus Erythematosus (SLE)
  • Atopic dermatitis (AD)  
  • Alopecia Areata (AA)  
  • Non Segmental Vitiligo (NSV)  
  • Hidradenitis suppurativa (HS)

ClinicalTrials.gov URL: https://clinicaltrials.gov/study/NCT04159597

 

Venetoclax

Indications:

  • Chronic Lymphocytic Leukemia (CLL)
  • Multiple Myeloma
  • Acute Myeloid Leukemia (AML)
  • Non-Hodgkin's Lymphoma
  • Acute Lymphoblastic Leukemia (ALL)
  • Amyloidosis
  • Plasma Cell Leukemia

ClinicalTrials.gov URL: https://clinicaltrials.gov/study/NCT03123029

EA Policies for Single Patient

AbbVie’s Pre-Approval Access programs are designed to provide access to investigational products prior to approval by the local regulatory agency. Availability will depend on the territory eligibility. A medical doctor must decide whether the patient might potentially benefit from receiving an investigational product based on the individual patient's medical history and program eligibility criteria.

 

Criteria:

  • The patient suffers from a serious or life-threatening illness or condition
  • There are no other suitable treatment options
  • The patient does not qualify for ongoing clinical trials